Protein Characterization and Identification - Global Strategic Business Report 2026: Secure Your Share of $31.6B by 2032

Detailed summary

Mass spectrometry advances, personalized medicine, proteomics and novel biologics are driving demand for precise protein analysisDublin, Nov. 13, 2026 (GLOBE NEWSWIRE) -- "Protein…

Mass spectrometry advances, personalized medicine, proteomics and novel biologics are driving demand for precise protein analysis

Dublin, Nov. 13, 2026 (GLOBE NEWSWIRE) -- "Protein Characterization and Identification - Global Strategic Business Report 2026" has been added to ResearchAndMarkets.com's offering.

The global protein characterization and identification market was valued at US$12.2 billion in 2025 and is projected to reach US$31.6 billion by 2032, expanding at a compound annual growth rate (CAGR) of 14.5%. The market outlook reflects rising demand for advanced protein analysis across drug discovery and development, clinical diagnostics, proteomics, personalized medicine, and next-generation biologics.

Protein characterization and identification remain central to biotechnology and biomedical research, supporting the analysis of protein structure, function, interactions, and biological pathways. These capabilities are increasingly important in the development and quality assessment of monoclonal antibodies, recombinant proteins, gene therapies, and cell-based treatments.

The growing complexity of biologic drugs is increasing the need for accurate analytical workflows that support product safety, efficacy, consistency, and regulatory compliance. Pharmaceutical and biotechnology companies are consequently investing in instruments, consumables, services, and software that can manage complex samples and produce reliable molecular data.

Mass spectrometry continues to play a leading role in protein analysis. Advances in high-resolution and tandem mass spectrometry are improving the sensitivity, accuracy, and throughput of protein identification, including the detection of low-abundance proteins in complex biological samples.

Progress in nuclear magnetic resonance spectroscopy, X-ray crystallography, bioinformatics, and analytical software is also strengthening structural analysis and data interpretation.

Personalized medicine represents an important growth opportunity…

Ad…

Opening of the article, excerpted from Yahoo Finance. To read the rest, open the article on the publisher's site.